Concurrent Infection of Hepatitis B Virus Negatively Affects the Clinical Outcome and Prognosis of Patients with Non-Hodgkin's Lymphoma After Chemotherapy

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Jul 18

PMID 23861969

Citations 11

Authors

Jie Chen

Jianmin Wang

Jianmin Yang

Weiping Zhang

Xianmin Song

Li Chen

Affiliations

Soon will be listed here.

Abstract

Hepatitis B virus (HBV) is hepatotropic and lymphotropic. HBV-infected individuals have an increased risk of developing malignant lymphoma, and the HBV infection rate in lymphoma patients is significantly higher than that in the general population. However, the exact mechanism and correlation between HBV infection and lymphoma onset and progression currently remain unclear. We retrospectively analyzed clinical data from non-Hodgkin's lymphoma (NHL) patients with different HBV infection statuses. The results showed that the HBV infection rate was significantly higher in patients with B-cell type and late stage of NHL. The chemotherapy efficacy for NHL patients with chronic active HBV infection was significantly lower than that for the patients with chronic inactive HBV infection, the patients with HBV carriers and the patients without HBV infection. In addition, the NHL chemotherapy activated HBV replication and caused significant liver dysfunction, which could further reduce the chemotherapy efficacy. Through Kaplan-Meier survival curve and log-rank analysis, we found that the HBV infection status in NHL patients was significantly correlated with the patients' progression-free survival (PFS) and overall survival (OS). Compared with the patients without HBV infection (PFS: 95% CI 47.915 to 55.640; OS: 95% CI 81.324 to 86.858), the PFS and OS of the patients with chronic active HBV infection were significantly shorter (PFS: 95% CI 9.424 to 42.589, P < 0.001; OS: 95% CI 42.840 to 82.259, P = 0.006). The study demonstrated that the sustained HBV replication in patients with chronic active HBV infection could be a key factor that influences the prognosis of NHL patients after chemotherapy, and thus may provide information for designing rational clinical treatments for NHL patients with different HBV infection statuses and improve the treatment efficacy and prognosis.

Citing Articles

LncRNA MALAT1 promotes Erastin-induced ferroptosis in the HBV-infected diffuse large B-cell lymphoma.

Bai X, Li J, Guo X, Huang Y, Xu X, Tan A Cell Death Dis. 2024; 15(11):819.

PMID: 39532842 PMC: 11557927. DOI: 10.1038/s41419-024-07209-0.

Hepatitis Virus-associated Non-hodgkin Lymphoma: Pathogenesis and Treatment Strategies.

Zhang W, Du F, Wang L, Bai T, Zhou X, Mei H J Clin Transl Hepatol. 2023; 11(5):1256-1266.

PMID: 37577221 PMC: 10412707. DOI: 10.14218/JCTH.2022.00079S.

Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma.

Park J, Chung S, Lee Y, Shin H, Hur M, Cho H Clin Mol Hepatol. 2023; 29(3):794-809.

PMID: 37196991 PMC: 10366791. DOI: 10.3350/cmh.2023.0057.

A novel prognostic nomogram for patients with extragastric mucosa-associated lymphoid tissue lymphoma: A multicenter study.

Li X, Hong H, Huang H, Zou L, Chen Z, Zhang Z Cancer Med. 2022; 11(18):3407-3416.

PMID: 35488377 PMC: 9487880. DOI: 10.1002/cam4.4702.

lncNBAT1/APOBEC3A is a mediator of HBX-induced chemoresistance in diffuse large B cell lymphoma cells.

Li J, Chen Y, Guo X, Bai X, Xu X, Han T Mol Ther Nucleic Acids. 2022; 27:1064-1077.

PMID: 35228900 PMC: 8850662. DOI: 10.1016/j.omtn.2022.01.015.

References

Thompson P, Tam C, Thursky K, Seymour J . Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge. Leuk Lymphoma. 2010; 51(9):1592-5. DOI: 10.3109/10428194.2010.509456. View

Engels E, Cho E, Jee S . Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010; 11(9):827-34. PMC: 2933963. DOI: 10.1016/S1470-2045(10)70167-4. View

Kim Y, Jeong S, Kim J, Lee S, Hwang J, Park Y . Chronic hepatitis B, non-Hodgkin's lymphoma, and effect of prophylactic antiviral therapy. J Clin Virol. 2011; 51(4):241-5. DOI: 10.1016/j.jcv.2011.05.004. View

Pei S, Chen C, Lee C, Wang M, Ma M, Hu T . Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2009; 89(3):255-62. DOI: 10.1007/s00277-009-0806-7. View

Ma Z, Shen Q, Chen G, Zhang D . Biological impact of hepatitis B virus X-hepatitis C virus core fusion gene on human hepatocytes. World J Gastroenterol. 2008; 14(35):5412-8. PMC: 2744172. DOI: 10.3748/wjg.14.5412. View

Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A . High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica. 2006; 91(4):554-7. View

Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao Y . Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol. 2011; 21(6):401-16. PMC: 3899457. DOI: 10.2188/jea.je20100190. View

Assogba B, Paik N, Rho H . Transcriptional activation of gammaherpesviral oncogene promoters by the hepatitis B viral X protein (HBx). DNA Cell Biol. 2004; 23(3):141-8. DOI: 10.1089/104454904322964733. View

Takai S, Tsurumi H, Ando K, Kasahara S, Sawada M, Yamada T . Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol. 2005; 74(2):158-65. DOI: 10.1111/j.1600-0609.2004.00376.x. View

10.

Fwu C, Chien Y, You S, Nelson K, Kirk G, Kuo H . Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan. Hepatology. 2011; 53(4):1217-25. DOI: 10.1002/hep.24150. View

11.

Kusumoto S, Tanaka Y, Mizokami M, Ueda R . Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009; 90(1):13-23. DOI: 10.1007/s12185-009-0359-5. View

12.

Marcucci F, Spada E, Mele A, Caserta C, Pulsoni A . The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma - a review. Am J Blood Res. 2012; 2(1):18-28. PMC: 3301438. View

13.

Tonziello G, Pisaturo M, Sica A, Ferrara M, Sagnelli C, Pasquale G . Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection. 2012; 41(1):225-9. DOI: 10.1007/s15010-012-0305-y. View

14.

Wang F, Xu R, Han B, Shi Y, Luo H, Jiang W . High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer. 2007; 109(7):1360-4. DOI: 10.1002/cncr.22549. View

15.

Chen M, Hsiao L, Chiou T, Liu J, Gau J, Teng H . High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma. Ann Hematol. 2008; 87(6):475-80. DOI: 10.1007/s00277-008-0469-9. View

16.

Tsutsumi Y, Ogasawara R, Miyashita N, Tanaka J, Asaka M, Imamura M . HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine. Int J Hematol. 2012; 95(5):588-91. DOI: 10.1007/s12185-012-1050-9. View

17.

Marcucci F, Mele A . Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood. 2010; 117(6):1792-8. DOI: 10.1182/blood-2010-06-275818. View

18.

Qiu M, Ruan D, Wang Z, Luo H, Teng K, Xia Z . The expression of hepatitis B virus surface antigen in 120 Hodgkin's lymphoma patients. Chin J Cancer. 2010; 29(8):735-40. DOI: 10.5732/cjc.010.10038. View

19.

Lim S, Fei G, Quek R, Lim L, Lee L, Yap S . The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol. 2007; 79(2):132-7. DOI: 10.1111/j.1600-0609.2007.00878.x. View

20.

Wang F, Xu R, Luo H, Zhang D, Jiang W, Huang H . Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer. 2008; 8:115. PMC: 2377276. DOI: 10.1186/1471-2407-8-115. View